Lawton C L, Blundell J E
Department of Psychology, University of Leeds, UK.
Psychopharmacology (Berl). 1993;112(2-3):375-82. doi: 10.1007/BF02244936.
The effects of six 5-HT anorectic agents, d-fenfluramine (5-HT releaser and reuptake inhibitor), fluoxetine (5-HT reuptake inhibitor), mCPP (5-HT1B/5-HT1C receptor agonist), RU24969 (5-HT1A/5-HT1B receptor agonist), MK212 (5-HT1C receptor agonist) and DOI (5-HT2/5-HT1C receptor agonist), and two non-5-HT anorectic agents, salbutamol (beta 2-adrenergic agonist) and d-amphetamine (catecholaminergic agonist), were examined in an experimental procedure designed to disclose selective effects on carbohydrate consumption. In this procedure, a revised version of what we have termed "The Classic Sclafani Paradigm", animals are presented with powdered Polycose as an optional carbohydrate supplement to hydrated chow (nutritionally complete diet). All drugs produced significant reductions in total (hydrated chow plus powdered Polycose) intake. However, only the 5-HT drugs DOI and fluoxetine exerted significantly stronger anorectic effects on intake of powdered Polycose than on intake of hydrated chow. d-Fenfluramine also showed a tendency to selectively suppress Polycose intake but this effect marginally failed to reach significance. These results suggest that when experimental conditions are favourable, what appears to be selective carbohydrate (Polycose) suppression can be demonstrated with certain 5-HT drugs. They also suggest that a selective effect on carbohydrate intake is not the most prominent feeding response to 5-HT drugs.
在一项旨在揭示对碳水化合物消耗的选择性影响的实验程序中,研究了六种5-羟色胺厌食剂,即右芬氟拉明(5-羟色胺释放剂和再摄取抑制剂)、氟西汀(5-羟色胺再摄取抑制剂)、mCPP(5-HT1B/5-HT1C受体激动剂)、RU24969(5-HT1A/5-HT1B受体激动剂)、MK212(5-HT1C受体激动剂)和DOI(5-HT2/5-HT1C受体激动剂),以及两种非5-羟色胺厌食剂,即沙丁胺醇(β2-肾上腺素能激动剂)和右苯丙胺(儿茶酚胺能激动剂)。在这个程序中,采用了我们所称的“经典斯克拉法尼范式”的修订版,给动物提供粉状聚葡萄糖作为水合食物(营养完整的饮食)的可选碳水化合物补充剂。所有药物均使总摄入量(水合食物加粉状聚葡萄糖)显著降低。然而,只有5-羟色胺药物DOI和氟西汀对粉状聚葡萄糖摄入量的厌食作用明显强于对水合食物摄入量的厌食作用。右芬氟拉明也表现出选择性抑制聚葡萄糖摄入量的趋势,但这种作用勉强未达到显著水平。这些结果表明,当实验条件有利时,某些5-羟色胺药物可表现出对碳水化合物(聚葡萄糖)的选择性抑制作用。它们还表明,对碳水化合物摄入量的选择性影响并非5-羟色胺药物最突出的摄食反应。